LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human ...

ABI-110 has the potential to offer a durable and effective solution by addressing the root causes of wet AMD at the genetic level.

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products.

Previously, under a third of NHS eye care services were offering OCT imaging. There were disparities based on region, as well, according to the NHS news release. Now, all NHS staff are being trained ...

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

The Gr8 Eye Movement campaign by Prevent Blindness and Regeneron emphasizes the critical role of caregivers in eye health, revealing significant gaps in caregivers' awareness of retinal diseases and ...

FYB203 has been recommended by the CHMP for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases.

Dosing in the first phase of the phase 1/2 OCU410ST GARDian trial for Stargardt disease is complete. The European Medicines Agency (EMA) has granted orphan medicinal product designation for OCU410ST ...

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio.